Immunomedics, Inc. Information Request Form
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) to Gilead Sciences, Inc. ("Gilead") (NASDAQ: GILD). Under the terms of the deal, Gilead will acquire Immunomedics for $88.00 per share in cash.
The Immunomedics merger investigation concerns whether the Board of Immunomedics has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.